The Evolving Landscape in CLL/SLL: Best Practice Clinical Applications of Current Evidence and New Guideline Recommendations

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL.

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This educational program is intended for oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL, taking into consideration the agent’s toxicity profile, prognostic variables, response to prior therapy, comorbidities, and patient preference
  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents with the similar molecular target used to treat CLL/SLL
  • Develop treatment plans to address unique clinical challenges, based on the available evidence and recommendations outlined in the NCCN Guidelines to optimize outcomes for patients with CLL/SLL
  • Evaluate the evolving role of measurable residual disease (MRD; often referred to as minimal residual disease), allogeneic hematopoietic cell transplant, and CAR T-cell therapy
Additional information
Supporters: 

Supported by educational grants from AstraZeneca, BeiGene, and Lilly.

Supported by independent educational grants from Merck & Co., Inc., Rahway, NJ, USA, and Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

Course summary
Available credit: 
  • 1.75 AAPA Category 1 CME credit
  • 1.75 ACPE contact hours
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation
Course opens: 
07/21/2023
Course expires: 
07/21/2024
Cost:
$0.00

Program Chair

Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Faculty

Jeremy Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma 
Massachusetts General Hospital
Boston, Massachusetts

Farrukh T. Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Division of Hematology/Oncology
University of Texas Southwestern Medical Center
Dallas, Texas

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Farrukh T. Awan, MD
Abbvie, Inc.: Consultant/Advisor/Speaker
Adaptive Biotechnologies: Consultant/Advisor/Speaker
ADC Therapeutics: Consultant/Advisor/Speaker
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
BeiGene: Consultant/Advisor/Speaker
Bristol Myers Squibb: Consultant/Advisor/Speaker
Cardinal Health Specialty Solutions: Consultant/Advisor/Speaker
Caribou Biosciences, Inc.: Consultant/Advisor/Speaker
Celgene Corporation: Consultant/Advisor/Speaker
Cellectar Biosciences, Inc.: Consultant/Advisor/Speaker
DAVA Oncology: Consultant/Advisor/Speaker
Epizyme: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker
Genmab A/S: Consultant/Advisor/Speaker
Gilead Sciences, Inc.: Consultant/Advisor/Speaker
Incyte Corporation: Consultant/Advisor/Speaker
Janssen Pharmaceutica Products, LP: Consultant/Advisor/Speaker
Johnson & Johnson: Consultant/Advisor/Speaker
Karyopharm Therapeutics: Consultant/Advisor/Speaker
Kite Pharma: Consultant/Advisor/Speaker
MEI Pharma: Consultant/Advisor/Speaker
Merck & Co., Inc.: Consultant/Advisor/Speaker
Pharmacyclics: Consultant/Advisor/Speaker; Grant/Research Support
Verastem, Inc.: Consultant/Advisor/Speaker

Jeremy S. Abramson, MD, MMSc
Abbvie, Inc.: Consultant/Advisor/Speaker
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
BeiGene: Consultant/Advisor/Speaker
Bristol Myers Squibb: Consultant/Advisor/Speaker; Grant/Research Support
Caribou Biosciences, Inc.: Consultant/Advisor/Speaker
Cellectar Biosciences, Inc.: Consultant/Advisor/Speaker
Cellectis SA: Grant/Research Support
Century Therapeutics: Consultant/Advisor/Speaker
Epizyme: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker
Genmab A/S: Consultant/Advisor/Speaker
Incyte Corporation: Consultant/Advisor/Speaker
Interius BioTherapeutics, Inc.: Consultant/Advisor/Speaker
Janssen Pharmaceutica Products, LP: Consultant/Advisor/Speaker
Kite Pharma: Consultant/Advisor/Speaker
Kymera Therapeutics: Consultant/Advisor/Speaker
Eli Lilly and Company: Consultant/Advisor/Speaker
Merck & Co., Inc.: Grant/Research Support
MorphoSys AG: Consultant/Advisor/Speaker
Mustang Bio: Consultant/Advisor/Speaker; Grant/Research Support
Ono Pharmaceutical Co., Ltd.: Consultant/Advisor/Speaker
Regeneron Pharmaceuticals, Inc.: Consultant/Advisor/Speaker
Seattle Genetics, Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consultant/Advisor/Speaker

Brian Hill, MD, PhD
Abbvie, Inc.: Consultant/Advisor/Speaker
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
BeiGene: Consultant/Advisor/Speaker
Bristol Myers Squibb: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker
Kite Pharma: Consultant/Advisor/Speaker
Novartis Pharmaceuticals Corporation: Consultant/Advisor/Speaker

NCCN and CCO Staff Disclosures

None of the planners/managers for this educational activity has relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.75 contact hours.

Pharmacists
NCCN designates this application-based continuing education activity for 1.75 contact hours (0.175 CEUs) of continuing education credit. UAN: JA4008196-0000-23-092-H01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.75 AAPA Category 1 CME credits. Approval is valid until July 21, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.75 AAPA Category 1 CME credit
  • 1.75 ACPE contact hours
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing